InfuSystem (NYSEAMERICAN:INFU) Posts Earnings Results, Beats Expectations By $0.01 EPS

InfuSystem (NYSEAMERICAN:INFUGet Rating) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01, MarketWatch Earnings reports. InfuSystem had a return on equity of 26.77% and a net margin of 11.64%.

NYSEAMERICAN:INFU opened at $9.33 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.25 and a current ratio of 1.51. InfuSystem has a 52 week low of $6.78 and a 52 week high of $21.89. The firm has a market cap of $191.90 million, a price-to-earnings ratio of 17.28 and a beta of 1.08.

INFU has been the subject of several analyst reports. Zacks Investment Research lowered InfuSystem from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th. Craig Hallum lowered their price objective on InfuSystem from $30.00 to $22.00 in a research report on Friday, February 11th.

In other news, Director Gregg Owen Lehman sold 20,000 shares of the stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $10.75, for a total value of $215,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Paul Andrew Gendron acquired 10,000 shares of InfuSystem stock in a transaction dated Friday, February 11th. The stock was bought at an average price of $10.67 per share, for a total transaction of $106,700.00. The disclosure for this purchase can be found here. 18.20% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of InfuSystem by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 298,758 shares of the medical instruments supplier’s stock valued at $5,087,000 after acquiring an additional 10,460 shares in the last quarter. Morgan Stanley raised its stake in InfuSystem by 165.2% in the second quarter. Morgan Stanley now owns 109,094 shares of the medical instruments supplier’s stock valued at $2,268,000 after buying an additional 67,950 shares in the last quarter. Nuveen Asset Management LLC raised its stake in InfuSystem by 26.4% in the fourth quarter. Nuveen Asset Management LLC now owns 82,865 shares of the medical instruments supplier’s stock valued at $1,379,000 after buying an additional 17,333 shares in the last quarter. Bank of New York Mellon Corp raised its stake in InfuSystem by 81.2% in the third quarter. Bank of New York Mellon Corp now owns 88,720 shares of the medical instruments supplier’s stock valued at $1,156,000 after buying an additional 39,762 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in InfuSystem by 27.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,227 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 5,435 shares in the last quarter. Institutional investors and hedge funds own 57.61% of the company’s stock.

InfuSystem Company Profile (Get Rating)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Featured Articles

Earnings History for InfuSystem (NYSEAMERICAN:INFU)

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.